Franklin Resources Inc Editas Medicine, Inc. Transaction History

Franklin Resources Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$8.32 - $13.21 $5,208 - $8,269	-626 Reduced 3.16%	19,173 $170,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $240,755 - $384,496	19,799 New	19,799 $243,000
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $131,648 - $258,340	-9,350 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$26.55 - $40.57 $13,301 - $20,325	501 Added 5.66%	9,350 $248,000
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $166,622 - $309,484	4,243 Added 92.12%	8,849 $363,000
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $66,147 - $119,736	-2,114 Reduced 31.46%	4,606 $261,000
Q1 2021 May 13, 2021	SELL	$39.71 - $90.58 $1,985 - $4,529	-50 Reduced 0.74%	6,720 $282,000
Q4 2020 Feb 10, 2021	BUY	$27.07 - $84.35 $183,263 - $571,049	6,770 New	6,770 $475,000

249

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.2M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.